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The immortal gods
have neither age nor death;







When Eos, goddess of the dawn, asked Zeus' permission to
marry Tithonus, a mortal, she also requested that he be given
eternal life. Unfortunately, she neglected to request eternal
youth for him as well. So while she remained an immortal,
strong and supple, Tithonus eventually weakened and withered
even though his molecular and cellulat clock continued to tick.
Eos' oversight has significance for scientists seeking to discover
the secrets of aging.
Most theories of aging fall into two general categories. The
first, and most studied, proposes an accumulation of lethal
events within the individual cell, leading to senescence and
death. One of the barriers to cellular longevity, called the
HayRick effect, after its discoverer, is the genetic time clock
that limits the number of divisions a cell is able to undergo.
But even if it were possible to extend cell division indefinitely,
physiological function would deteriorate, as Tithonus' did.
Professor Anthony Cerami, who heads The Rockefeller Uni-
versity's laboratory of medical biochemistry, takes another ap-
proach. He is investigating the process from the standpoint of
age-associated diseases or deterioration. "Our research is con-
cerned not so much with extending the lifespan of an individual
as with making old age healthier," he says. For the past twelve
years, his laboratory has made remarkable discoveries indicating
that many of the functional breakdowns associated with age
proceed from a single, fundamental chemical teaction. Condi-
tions such as cataracts and atherosclerosis, to cite two prime
examples, result from a commonplace chemical reaction be-
tween the sugar glucose and the proteins that com-
prise the body's metabolic machinery and structural
framework.
''AGE'' AND AGING
Until recently, glucose was generally considered a
stable and innocuous molecu.le serving as a central
source for energy. Scientists have since learned that
metabolism is not its only activity, and that this
abundant and ubiquitous sugar is not always benign.
Most biological activities are triggered by chemical
catalysts called enzymes. Glucose, however, has the
ability to react with proteins and with nucleic acids
(the generic material) through simple proximity, a
process called nonenzymatic glycosylation. '1\ lot of
complicated chemistry goes on," says Dr. Cerami,
"and if the reaction is permitted to continue, eventu-
ally it produces brownish-yellow pigments that can
bind two molecules together." Appropriately, Dr.
Cerami has named the resulting pigments '1\GE,"
for advanced glycosylated end-products. This synthesis of
glucose-modified proteins is independent of the amount of
sugar we consume. The body can produce glucose from carbo-
hydrates and other foodstuffs, so that the formation of AGE is
a continuous, life-long process wherever glucose is permitted
to react with proteins.














Glm'ose binds to proteins in
arterial watt (A), rearranges
itself (B), and binds to other
protein strands (C) or to
cholesteral-bearing low-density
lipoproteins (D). Aminoguan-
idine inhibits cross-linking (E)
and thus may prevent the
hardening and narrowing of
arteries that occur in diabetes and
agtng.
The skin of a roasted chicken turns brown because the dehy-
dtation that occurs during cooking accelerates the formation
of AGE. The same teaction turns bread into toast. The effects
of AGE ovet time can be observed simply by comparing dtied
apricots from a health food store, brown and hard, with the
artificially preserved supermarket variety, bright orange and
soft. Pathologists have observed that the bones of older people
are browner than the bones of youngsters. "Like untreated
apricots," says Dr. Cerami, "we're browning all the time."
AGE does more than just discolor tissue. As Dr. Cerami
'explains, ':AGE acts as a chemical glue to attach molecules to
one another, forming what we call a cross-link. That is why
overcooked meat is so difficult to slice and chew. You are literally
sawing through cross-linked proteins with your knife and grind-
ing them down with your teeth." Importantly, these same
glucose-derived cross-links have been traced to many physio-
logic manifestations of old age.
Since the formation of AGE occurs during the later stages
of nonenzymatic glycosylation, the proteins involved must be
long lived. Many of the crystallin proteins in eye lens remain
intact our whole lives. Dr. Cerami's experiments have shown
that cataracts can result from cross-linked proteins accumulat-
ing in the lens, preventing light from passing to the retina.
His research has also demonstrated that cross-linked proteins
can form in the tissue of the lungs, heart, and arteries, con-
tributing to their progressive inelasticity. Glucose can react to
form cross-links with collagen, the major protein in skin and
connective tissue.
Another manifestation of aging is the impairment of DNA
fun·ction. In addition to transmitting our inheritance from
generation to generation, DNA, deoxyribonucleic acid, encodes
the instructions that cells need to make proteins. Based on
recendy published work, Dr. Cerami and former bio-medical
fellow Richard S. Bucala believe that AGE may be involved in
the chromosomal aberrations and breakage in DNA molecules
characteristic of old cells.
THE POWER OF CHEMISTRY
Oddly enough, chickens brought Dr. Cerami to the exploration
of science. When he was a boy growing up on a farm in New
Jersey, a chicken infection called coccidiosis would regularly
wipe out half of his family's flock. In the 1950s, a new drug
was introduced against the disease. "It seemed miraculous,"
he recalls. "We would give the drug to the chickens and they
didn't die. I thought it would be wonderful to be able to use
chemistry as a way ofdoing something as meaningful as that."
At Rutgers University's College of Agriculture he learned
about basic chemistry and animal husbandry. His training as
a research scientist began at The Rockefeller University, where
he studied nucleic acid chemistry with Professor Edward Reich
in the laboratory of Nobel Laureate Edward Tatum. After receiv-
ing his Ph.D. in 1967, he spent some time at Harvard Medical
School learning the medical application of biochemistry. In
1969, he was invited to return to Rockefeller, where he has
remained.
Dr. Cerami's first clue to the far-reaching effects of nonen-
zymatic glycosylation came from work he was doing in the
1970s on the blood disease sickle cell anemia. The disease is
so named because the red blood cells of its vierims become
sickle-shaped in the absence of oxygen instead of remaining
oval. These sickled cells can block blood vessels and starve
tissues of oxygen. Previous experiments elsewhere had reported
that urea, a compound excreted by the kidneys, prevents sick-
ling. But urea seemed to Dr. Cerami an unlikely therapy since
the amounts needed would be unsafe.
Dr. Cerami remembered as a graduate student attending a
lecture by Stanford Moore, one of the Rockefeller's pioneer
protein chemists. In the lecture, Dr. Moore discussed the active
properties of the small amounts of cyanate normally found in
urea solutions. The recollection suggested a course of experi-
mental inquiry. And, in fact, Dr. Cerami and Professor James
Manning, a Rockefeller colleague, did find that cyanate could
prevent sickling. However, it was still not sufficiently safe.
~ Patients given rhe compound began to form cataracts and to
lose the proteerive myelin sheath around petipheral nerves in
the legs, a condition called peripheral neuropathy. While the
side effects ruled our cyanate as a treatment for sickle cell
disease, they provided a springboard to a new area of research.
Both cataracts and peripheral neuropathy are frequent com-
plications of diabetes. Dr. Cerami wondered why diabetics
displaYEd the same problems as sickle cell patients treated with
cyanate. His hunch was that "in diabetes thete was something
like cyanate reacting with the hemoglobin in the blood, which
was also reacting with the lens crystallins in the eye and the
nerves of the leg." That something turned our to be glucose.
From previous work in the laboratory of Helen Ranney at
Albert Einstein College of Medicine, Dr. Cerami knew that a
type of hemoglobin, called hemoglobin Ale> is elevated in
diabetic patients. Further research by Dr. Cerami and his col-
league Ronald J. Koenig revealed that hemoglobin Ale is a
modification of hemoglobin resulting from chemical interaction
with glucose, and that the more glucose present in the patient,
the more rapidly hemoglobin Ale was made.
This led to the realization that the measurement of hemo-
globin Ale could not only identify the presence of diabetes but
could also provide an accurate measurement of the average
glucose concentration in the blood over the course of a month.
Today, this finding is applied by physicians throughout the
world to assist in the diagnosis and management of diabetic
patients. On an investigative level, the observation of how
glucose reacts with long-lived proteins like hemoglobin pro-
vided a new perspective for studying how our bodies age.
Just as diabetes provided a clue that glucose and proteins
formed AGE pigments, the chemical structure of the AGE has
since provided a clue to a new treatment for the complications
of diabetes. The rate of AGE synthesis is dependent both on
time and on the amount of glucose in the blood. Because the
blood glucose concentration is greater in diabetics than in
normal people, they exhibit AGE-related diseases earlier, par-
ticularly cataracts and vascular problems. Biochemically, dia-
betics age more quickly than non-diabetics.
Proteins in the blood vessel wall can undergo a chemical
rearrangement with glucose to form molecular traps. These
traps can snare proteins floating by in the blood. The attached
proteins can colleer in the vessels and block the free flow of
blood. Among the proteins that become stuck is the cholesterol-
containing LDL, or low-density lipoprotein, a major con-
tributor to atherosclerosis and heart disease. Dr. Cerami
reasoned that if a drug could be found to block the AGE traps,
the plasma proteins would be deprived of anchoring sites and
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Glucose-modified red blood cells
surrounded and ingested by
macrophages .
Current research by Helen
Vlassara focusses on the role of
white cells called macrophages in
the removal of aging proteins.
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Dr. Cerami with laboratory
colleague Mary R. Rifkin,
right, and graduate student
Annette Lee. In addition to their
research posts, Dr. Cerami serves
as dean of graduate and
postgraduate studies and Dr.
Rifkin as an associate dean.
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the arrery-clogging process interrupted.
For years, food chemists have treated fruits and other foods
with sulfur dioxide co prevent browning. Michael Brownlee,
of the Cerami laboracory, tried sulfur dioxide with proteins
incubated with glucose. While it prevented discoloration, it
did not prevent cross-linking. The search widened co other
chemicals. Peter Ulrich, who was working on the chemical
structure of AGE, joined forces with Dr. Brownlee in identify-
ing the compound aminoguanidine. This has proven, at least
in animal trials, co be capable of preventing the formation of
AGE cross-links and the adhesion of plasma proteins co the
vessel walls. Further research is needed before the drug can be
used clinically, but its potential for inhibiting vascular compli-
cations, says Dr. Brownlee, "is an exciting possibility we'll be
exploring over the next few years."
Not all proteins with AGE are fated co survive. When glucose
and protein are placed cogether in the test tube, many more
cross-links are formed than occur in nature. Clearly, the body
has its own mechanism for the recognition and removal of AGE
molecules. If this mechanism could be identified and harnessed,
age-associated disease might be slowed or stopped naturally
without the introducrion of cross-link-inhibiting drugs.
A clue co the body's mechanism for protein removal was
found by Helen Vlassara while she was studying the removal
of the myelin sheath of peripheral nerves of diabetics. Having
shown that glucose reacrs with the myelin protein to form
AGE, Dr. Vlassara noticed that macrophages could specifically
take up these modified proteins. Macrophages are white blood
cells that can act as the immune system's scavengers. She has
since demonstrated that highly-specific recepcors on the macro-
phage cell surface selectively "recognize" senescent proteins
that need to be disposed of. "Unfortunately, as we become
older, macrophages become less efficient and tend to leave
behind a certain amount of AGE, which accumulates over time,"
Dr. Vlassara explains. She is currently srudying the AGE recep-
cor on the macrophage and developing strategies to speed up
the removal of targeted cross-linked proteins.
PARADOXES
In addition to investigating the diseases of aging, Dr. Cerami's
laboracory has been studying the wasting of the body that
occurs in animals or people with parasitic diseases or rumors.
Conventional medical wisdom decreed that this wasting
phenomenon was a result of parasites or tumors teeding off
their hosts' energy. But when Dr. Cerami examined samples of
blood from cows and rabbits infected with trypanosomes, the
agents of African sleeping sickness, he found the number of
parasites surprisingly low. It did not seem possible that so few
assailants were causing such extreme emaciation and lethargy,
a condition called cachexia (pronounced ka-KEX-ee-ah). Further
investigation revealed a further paradox. The blood of the ani-
mals was rich in fat. "We were faced with a situation," Dr.
Cerami says, "that required of us co ask, 'what's going on here?' "
Crucial co the body's proper utilization of fats is the enzyme
lipoprotein lipase. Without it, complex fatty substances cir-
culating in the blood cannot be metabolized and scored as
energy in cells. From blood samples of cachectic animals,
Masanoba Kawakami of the laboratory was able co identify a
molecule that prevented the synthesis of the enzyme. This
suggested that the molecule's role may be the mobilization of
energy for quick response against invading microorganisms.
When infection becomes chronic, however, the continuing pres-
ence of the molecule, which they dubbed cachecrin, becomes
a fatally damaging faccor.
Cachecrin appears to cause cachexia in patients infected with
bacteria as well "as in those with parasitic disease. The labora-
tory's research also indicates that cachecrin may be one of the
body's major mediators of the fatal condition associated with
infection called septic shock.
But the big surprise was still to come. When cachectin's
molecular composition was identified by Bruce Beutler, who
has recently moved co the Howard Hughes Medical Institute
in Dallas, it was found to be identical to tumor necrosis factor,
or TNF, a compound that is being evaluated as a drug against
cancer. Discovered at Memorial Sloan-Kettering Cancer Center,
TNF has the ability to kill cerrain tumor cells. To what extent
the discovery of its cachexia and shock-inducing properries will
make it necessary co modify its use in cancer therapy is a
question under intensive investigation.
Substances like glucose and cachectin that play more than
one biologic role are recurring themes in Dr. Cerami's research.
They are proving to be pivotal elements in explaining extremely
complex phenomena. "It is my hope," says Dr. Cerami, "that
our studies will provide new insight into some of the medical
questions that have intrigued mankind since earliest times.
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